1 2 3 4 5 6 7 8	Laboratory Readiness and genomic surveillance of Covid-19 in the Capital of Brazil
9 10 11 12	Fabrício Vieira Cavalcante ¹ ¶,Christina Pacheco Santos Martin ¹ ¶, Gustavo Saraiva Frio ² ¶, Rodrigo Guerino Stabeli ³ ¶, Leonor Maria Pacheco Santos ¹ ¶
13	
14	¹ Universidade de Brasília, Brasília, Brasil.
15 16	² Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Rio Grande do Sul, Brasil.
17	³ Fundação Oswaldo Cruz (FIOCRUZ), São Paulo, Brasil
18	
19	
20	* Corresponding author
21	E-mail: fabricioocavalcante@gmail.com
22	
23	[¶] These authors contributed equally to this work.
24	
25	
26	
27	
28	
29	
30	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Abstract

Objective: Analyze the diagnostic readiness to Covid-19 and the genomic surveillance
 of SARS-CoV-2 in Brasília, the capital of Brazil.

34 **Method:** Retrospective, cross-sectional study, with data from: cases/deaths - Ministry

of Health; RT-PCR analyzes Brasília Central Public Health Laboratory (LACEN);
 genomics - Global Initiative on Sharing All Influenza Data (GISAID).

Results: In March 2021, with the Gamma variant being predominant, RT-PCR
dosages by LACEN reached their peak, followed by a reduction, possibly due to the
start of vaccination. New peaks were observed in September 2021 and January 2022.

The average time for releasing RT-PCR results was reduced from eight days (July 2020), to around eight hours in 2023. The participation of private laboratories was evident in sequencing the SARS-CoV-2 variants of concern in Brasília (n=1,897). LACEN received 571 samples, sequencing 50%. A decrease in the incidence of cases and deaths due to Covid-19 was noted in the years 2022 to 2023, following the national

45 trend.

46 **Conclusion:** LACEN maintained RT-PCR dosages satisfactorily throughout the 47 period. Regarding the genomic surveillance of SARS-CoV-2, the vast majority of 48 samples were sequenced by private laboratories and the sequencing predicted by 49 LACEN was not covered in its entirety.

50

51 Key-words: Covid-19. Public Health Laboratory Services. Epidemiological
52 Surveillance Services. Genomic Surveillance. Brasília. Brazil.

53

54 Introduction

55 Covid-19 emerged in China at the end of 2019 and spread quickly to several countries 56 such as the United States of America and countries in South America [1,2], infecting 57 thousands of people around the world. The World Health Organization (WHO) decided 58 to declare a Public Health Emergency of International Concern (PHEIC) on March 11, 59 2020, due to the high rate of contagion of SARS-CoV-2 [3]. Currently, Covid-19 is

better controlled and the WHO decreed on May 5, 2023 the end of PHEIC regarding
SARS-CoV-2 [4].

To achieve control and mitigation of Covid-19, several strategies were necessary, such as the use of a mask, social distancing[5], management of health inputs and financial resources, investment in scientific research[6], treatments, vaccine development[7] and timely diagnosis[8].

66 Among the measures used to mitigate the disease, is population testing, aiming for early diagnosis and enabling syndromic surveillance, providing support for planning 67 68 quarantine and other interventions appropriately[9]. The Reverse Transcription Polymerase Chain Reaction (RT-PCR) method is a gold standard test for diagnostic 69 confirmation and for use in public health laboratories[10], being disseminated in 70 several countries as a successful strategy for mitigating Covid-19[11]. In Brazil, the 71 first reports of laboratory diagnosis for SARS-CoV-2 occurred in February 2020, 72 restricted to the National Influenza Center (NIC). The expansion of RT-PCR tests 73 occurred in March 2020, when the NIC trained the all the 27 state Central Health 74 Reference Laboratories (LACENs) and they began to receive the necessary inputs to 75 carry out the diagnostic method[12]. 76

In view of this context and in line with the principles of the Unified Health System (SUS), 77 the Health Care Network (RAS), has the responsibility of the integrality of health 78 79 actions and services. The LACEN Laboratories assumes its leading role in this epidemiological scenario, since the organizational and operational structure of the RAS 80 is made up of support systems, including diagnostic and therapeutic support[13]. In the 81 82 meantime, it is understood that diagnostic support permeates all levels of health care and is of important relevance for strengthening the RAS, in order to support the 83 planning of interventions. 84

Given this, the study aims to analyze the diagnostic response capacity to Covid-19 and
the genomic surveillance of SARS-CoV in a timely manner, during the PHEIC period
in Brasília, capital city of Brazil.

88

89 Method

90

This is a retrospective, cross-sectional, exploratory study, based on secondary data in the public domain. It covered the pandemic period, that is, the duration of the Public Health Emergency of International Concern: March 2020 to May 2023.

Public, official data on Covid-19 cases and deaths available on the Ministry of Health portal were considered for the study[14]. Data on vaccination coverage in Brasília were obtained from the Covid-19 Vacinometer portal of the Ministry of Health[15], considering vaccination since the month of January 2021 with a vaccination schedule of second dose or single dose, third dose, booster and additional doses until May 2023. Data from the bivalent vaccine were not included, as there was no specification of which dose was being applied.

Data on diagnostic analyzes were extracted from the InfoSaúde-DF portal of the city of Brasília Health Department[16], including all samples received and analyzed for Covid-19 detection by the RT-PCR method at the Brasília LACEN. The average time for releasing the lab results, in days, was also analyzed.

To identify the dominant variants, throughout the pandemic period, the results of the sequenced genomes of Brasília patients were extracted from the Global Initiative on Sharing All Influenza Data (GISAID) database[17]. The originating laboratories (which provided the samples) and the sending laboratories (which sequenced the genetic

material)[18] were also identified. The total number of genomes sequenced was
analyzed by originating and sending laboratory, by type of variant and number of cases
for Covid-19 for the period from March 2020 to May 2023.

Data consolidation was done in the Excel program (Microsoft Office, 2016). The 112 correlation of the variable 'time for release of sample results in days' and the number 113 of samples per month/year, vaccination schedule (primary and first booster) and 114 115 deaths for the years 2020 to 2023 was analyzed, using the Pearson Correlation Coefficient, in Stata (version 18). Data relating to the SARS-CoV-2 variants of concern 116 117 (VOC) established by the WHO[19] per sampling period in Brasília were analyzed according to the month of sample collection and their classification: Alpha, Gamma, 118 Delta and Omicron. 119

As it is secondary data in the public domain, this study does not require approval by the Ethics Committee for research with human beings[20].

122

123 **Results**

The city of Brasília LACEN Laboratory analyzed a total of 500,789 samples using the 124 RT-PCR method, with 2021 being the year with the highest number of analyzes 125 (n=264,738), followed by 2020 (n=165,500), 2022 (n=58,050) and 2023 (n=12,501). 126 Comparing the number of analyzes using the RT-PCR method with the number of 127 128 Covid-19 cases in Brasília (Figure 1), in 2020 the number of analyzes for diagnosing Covid-19 increased until July/August and then reduced, returning only when the Alpha 129 variant becomes predominant in Brasília, in December 2020. From January 2021, 130 when the Gamma variant becomes predominant, an oscillation in morbidity due to 131 Covid-19 in Brasília is noted, which is accompanied by a similar oscillation in the 132

number of RT-PCR analyzes in the period. In September 2021, the predominance of
 the Delta variant was evident, accompanied by an increase in laboratory analyzes and
 cases for Covid-19, when compared to the previous month (Figure 1).

It is noteworthy that with the predominance of the Omicron variant, the number of cases 136 breaks records in January 2022 (86 thousand cases) and, again, in June of the same 137 year (95 thousand cases) causing a "blackout" in laboratory response capacity in 138 139 Brasília. This is because the increase in RT-PCR analysis carried out for Covid-19 in these months fell far short of the demand for registered cases, especially in June 2022 140 141 (95 thousand cases versus 6 thousand analyzes carried out). Throughout 2023, there was a decrease in analyzes and the number of cases in Brasília (Figure 1), following 142 the national trend. 143

144

[Insert Figure 1. Monthly number of RT-PCR analyzes carried out at the
 Central Public Health Laboratory and number of Covid-19 cases, compared with
 the SARS-CoV-2 variant predominant in Brasília, 2020 to 2023.]

148

When observing the number of deaths from Covid-19 in Brasília, it is possible to notice 149 a fluctuation in their number over the three years, with the highest occurrence in April 150 2021, a period in which the Gamma variant was predominant. The peak of deaths in 151 Brasília occurred in April 2021 (1,769 deaths), precisely one month after the peak of 152 samples analyzed by RT-PCR (33,286 samples). After this date, there was a decrease 153 in the number of deaths from the disease over the months and years, reducing to less 154 than 10 deaths per month from August 2022 onwards. It is worth noting that the 155 laboratory "blackout" occurred in June 2022 was not reflected in an increase in deaths, 156

probably due to the characteristics of the Omicron variant: high transmissibility
 accompanied by lower lethality, compared to other strains of interest (Figure 2).

159

[Insert Figure 2. Monthly quantity of RT-PCR analysis carried out at the
 Central Public Health Laboratory and number of deaths from Covid-19,
 compared with the SARS-CoV-2 variant predominant in Brasília, 2020 to 2023.]

163

Figure 3 shows the comparison between the number of deaths, of people vaccinated 164 165 - initial and booster schedule - and the emergence of variants of concern. According to data from the Ministry of Health, the population of Brasília in 2023 was 3,015,268 166 people. When Brasília reaches 50% of the vaccinated population (September 2021), 167 the number of analyzes reduced significantly, rising again only in the peaks caused by 168 the Omicron variant. The month of September 2021 is when the booster dose begins 169 to be applied, which also contributes to the reduction in the number of deaths in the 170 subsequent months. The peak of deaths, as previously identified, occurred in April 171 2021, in line with the progress of the vaccination schedule. 172

173

Insert Figure 3. Number of registered deaths, vaccination schedule and
 predominant SARS-CoV-2 variants in Brasília, 2020 to 2023.]

176

As far as the average time for releasing results by the LACEN, it was longer in the months of July 2020 (around eight days for release), followed by the months of June (three days), May and August, both around two days for the analysis results to be released. It is noteworthy that for the years 2021, 2022 and 2023 the average number of days to release exam results was less than one day, followed by a decrease

- in January 2021 from 0.99 to 0.28 to obtain the exam result for Covid-19 (Table 1).
- 183 The average time for releasing RT-PCR results has reduced from up to 8 days in 2020,
- to around eight hours in 2023.
- 185
- **Table 1.** Month and average release period in days of the results of RT-PCR analysis from the
- 187 Central Public Health Laboratory, Brasília, 2020 to 2023.

Month/Year	2020	2021	2022	2023
	Monthly aver	rage, in days, for re	eleasing RT-PCR at	nalysis results
January	•	0.99	0.77	0.28
February		0.52	0.52	0.33
March	0.79	0.94	0.39	0.35
April	0.79	0.69	0.41	0.29
May	2.12	0.79	0.39	0.38
June	3.89	0.95	0.47	
July	8.33	0.57	0.45	
August	2.51	0.45	0.35	
September	1.03	0.92	0.30	
October	0.69	0.77	0.28	
November	0.62	0.44	0.23	
December	1.34	0.43	0.34	

188

Source: elaborated by the authors from InfoSaúde-DF¹⁶

189

It is important to highlight the correlation between the variables of interest in this work (number of RT-PCR analyses, confirmed cases, deaths, total number of people with the initial vaccination schedule and with the booster dose). There is no significant correlation between the number of cases and vaccination in Brasília. 194 It should be noted, however, that the number of RT-PCR analyzes for Covid-19 is 195 positively correlated with the number of cases (47.35%) and the number of deaths in 196 the month (80.51%). On the other hand, the advancement of vaccination is negatively 197 correlated with the number of cases: initial scheme (-85.40%) and booster dose (-198 88.47%). Initial and booster vaccinations are negatively correlated with the number of 199 deaths (-75.99% and -83.71%, respectively). As expected, the Initial Schedule and 200 Booster Dose are highly correlated (90.79%).

Evaluating the provenance of the SARS-CoV-2 sequences available in the GISAID database in Brasília (Figure 4), it is observed that a large part of the samples were sequenced by private laboratories, the vast majority by laboratories from the DASA group (1,897) and a small portion of the samples collected by the Hermes Pardini Institute (43).

Among public laboratories, LACEN stands out, which received 571 samples and 206 managed to sequence more than 50% (293). In sequencing the samples, there was 207 significant participation by FIOCRUZ in the Respiratory Virus and Measles Laboratory 208 (193), the Adolfo Lutz Institute (65) and research laboratories at Brazilian public 209 universities such as the University of Brasília – UNB (55), Federal University of Minas 210 Gerais - UFMG (6) and Federal University of Goiás - UFG (5). Some American 211 laboratories, from the University of Washington, also worked on sequencing SARS-212 213 CoV-2 samples from the Federal District: Virology Lab (7) and Laboratory Medicine and Pathology (6) (Figure 4). 214

215

[Insert Figure 4. Characterization of the number of Covid-19 samples
 received and sequenced in public and private national and international
 laboratories for demand in Brasília from 2020 to 2023.]

219

220 **Discussion**

221

The data from the present study show an increase in the number of RT-PCR analyzes 222 in Brasília in April 2020, in line with the arrival of the first batch of 10 million tests 223 purchased by the Ministry of Health (MS) to expand coronavirus testing in the 224 country[21], in addition to peaks in analyzes by the Brasília LACEN that coincide with 225 the predominance of the different variants of SARS-CoV-2, with the last identified, and 226 less lethal, Omicron variant. The Omicron variant appears in a scenario of 227 implementation of the vaccination schedule and release of booster doses and in the 228 midst of the third wave of morbidity caused by Covid-19[22]. 229

230 A decrease in RT-PCR analyzes is evident from September 2021 onwards, in Brasília, possibly due to the introduction of rapid tests in Brazil: some of them only allowed the 231 identification of antibodies (negative or positive result, without specifying the type), 232 while other tests track IgM and IgG antibodies distinctly[23]. These findings are in line 233 with the MS initiative to start rapid testing by antigen test in Brasília through the 234 National Testing Plan for Covid -19 in August 2021[24], and which the following year 235 had its second edition called the National Plan for Expansion of Testing for Covid-19 236 (PNE - Test), that aimed to expand diagnosis for Covid-19 through rapid antigen 237 238 testing in symptomatic and asymptomatic individuals based on the care diagnosis strategy, active search and screening[12]. 239

The decrease in RT-PCR analyzes at the Brasília LACEN also comes from Anvisa's authorization through Collegiate Board Resolution (RDC) n° 377 of April 28, 2020[25], which allows pharmacies and drugstores to carry out rapid tests to detect Covid-19,

on an exceptional and temporary basis. These hypotheses are in line with the literature 243 review[26], which describes that serological tests are widely used to mitigate SARS-244 CoV-2 but points the limitations and advantages in their applicability, which are: the 245 possibility of the method not detecting the disease in asymptomatic patients, in 246 addition to not being adopted exclusively as a parameter for ruling out infection. 247 Among its advantages is the low cost of acquiring the tests when compared to the RT-248 249 PCR method, which is evident from the economic analysis study[27] that highlight the advantages of serological tests in relation to the reduction in total costs for health 250 251 services, ease of use, decentralization in places without laboratory support and test response time. However, a disadvantage is that not all results from these tests were 252 incorporated into the information system centralized at the Ministry of Health, which 253 makes it difficult for the health authority to monitor the evolution of the pandemic from 254 then on. The fact is in line with the limitation evidenced by Leite et al., (2021)[28]: the 255 difficulty in implementing information regarding the performance of laboratories trained 256 to face SARS-CoV-2 in the Regions of the Americas. 257

Regarding response time, the longest average number of days to release results by Brasília LACEN was eight days in July 2020 when compared to all other months and years analyzed. This lag time is within the time parameters for releasing results within three days, as explained by the Ministry of Health[29] regarding the estimated time for tests to detect Covid-19: rapid antigen test (TR-Ag) with a time of 20 minutes; antigen self-test (AT-Ag) with a time of 20 minutes and the RT-PCR with a time of 72 hours (3 days).

Of the 2,528 Covid-19 samples sequenced from Brasília, only 11.6% were carried out by the Brasilia LACEN, thus requiring the collaboration from other public and private laboratories, teaching and research institutions, accompanied by a global shortage of

inputs related to assistance and laboratory diagnosis[12]. Furthermore, the virus mutation process explains the appearance of the Alpha, Gamma, Delta and Omicron variants in Brasília, plus the reinfection of the disease, the decrease in the effectiveness of vaccines and the decrease in sensitivity to diagnostic tests, reinforcing the need to maintain non-pharmacological measures and the acceleration of immunization as a strategy for managing and controlling the circulation of the virus and new mutations[22,30].

This study presents limitations inherent to studies with secondary data, such as the occurrence of inaccuracy and/or incompleteness of data, the use of absolute data on both cases and deaths, which makes it impossible to verify the incidence of the disease and mortality rate, in addition to be an exploratory study without aiming to search for causal results.

It can be seen that Brasilia LACEN response capacity was correlated with the number of cases and deaths due to Covid-19, due to the monitoring of the diagnostic sector in carrying out RT-PCR analyzes that fluctuated during the period analyzed. Despite not having a positive correlation between vaccination and the number of cases and deaths, it is noted that vaccination coverage was associated with a decrease in the transmissibility of the disease and consequently in the number of deaths from Covid-19.

The Brasília LACEN had a decrease in the demand for RT-PCR analyzes in the years 2022 and 2023, however, throughout the respective year it maintained an average of less than one day to release test results in a satisfactory manner based on the time estimated by the Ministry of Health. Regarding the genomic surveillance of SARS-CoV-2 in Brasília, the vast majority of samples were sequenced by private laboratories

and those sequenced by Brasilia LACEN were not covered in their entirety for the

293 years 2020 to 2023.

294 This study showed satisfactory results in the diagnostic readiness to SARS-CoV-2 in

Brasília. It discuss and provides strategies that will contribute to government and

health entities, both nationally and internationally, to increase laboratory readiness,

both to face Covid-19 and other viral health crises that may emerge.

298

299 **References**

- Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First
 Case of 2019 Novel Coronavirus in the United States. N Engl J Med [Internet].
 2020 Mar 5;382(10):929–36. Available from:
- 303 http://www.nejm.org/doi/10.1056/NEJMoa2001191
- Álvarez RP, Harris PR. COVID-19 en América Latina: Retos y oportunidades.
 Rev Chil pediatría. 2020;91(2):179–82.
- OPAS OPA da S. OMS afirma que COVID-19 é agora caracterizada como pandemia [Internet]. 2020 [cited 2024 Jan 10]. p. 1. Available from: https://www.paho.org/pt/news/11-3-2020-who-characterizes-covid-19pandemic#:~:text=OMS afirma que COVID-19 é agora caracterizada como pandemia,-Copied to clipboard&text=11 de março de 2020,agora
- 311 caracterizada como uma pandemia
- OPAS OPA da S. OMS declara fim da Emergência de Saúde Pública de Importância Internacional referente à COVID-19 [Internet]. 2022 [cited 2024 Jan 10]. p. 1. Available from: https://www.paho.org/pt/noticias/5-5-2023-omsdeclara-fim-da-emergencia-saude-publica-importancia-internacional-referente
- 5. Garcia LP. Uso de máscara facial para limitar a transmissão da COVID-19. Vol. 29, Epidemiologia e Serviços de Saúde. scielo ; 2020.
- Rosa MFF, da Silva EN, Pacheco C, Diógenes MVP, Millett C, Gadelha CAG,
 et al. Direct from the COVID-19 crisis: research and innovation sparks in
 Brazil. Heal Res Policy Syst [Internet]. 2021;19(1):10. Available from:
 https://doi.org/10.1186/s12961-020-00674-x
- Pinto GS, Hung M, Okoya F, Uzman N. FIP's response to the COVID-19
 pandemic: Global pharmacy rises to the challenge. Res Soc Adm Pharm
 [Internet]. 2021;17(1):1929–33. Available from:
- https://www.sciencedirect.com/science/article/pii/S1551741120307440
- 8. Cavalcante FV, Oliveira A, Araujo SQ de, Pacheco C, Sacco R da CC e S.
 Testes diagnósticos nacionais: insumos essenciais para a vigilância sindrômica da Covid-19. Vol. 46, Saúde em Debate. scielo ; 2022.
- Mayr V, Nußbaumer-Streit B, Gartlehner G. Quarantine Alone or in
 Combination with Other Public Health Measures to Control COVID-19: A Rapid
- Review. Gesundheitswesen [Internet]. 2020;82(6):501–6. Available from:

332		http://europepmc.org/abstract/MED/32413914
333	10.	Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al.
334		Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
335		Eurosurveillance. 2020;25(3):2000045.
336	11.	Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al.
337		Diagnostic Testing for Severe Acute Respiratory Syndrome–Related
338		Coronavirus 2. Ann Intern Med [Internet]. 2020 Apr 13;172(11):726–34.
339		Available from: https://doi.org/10.7326/M20-1301
340	12.	Ministério da Saúde B. Diagnosticar para cuidar [Internet]. Brasília: Ministério
341		da Saúde; 2021. p. 71. Available from: https://www.gov.br/saude/pt-
342		br/assuntos/coronavirus/publicacoes-tecnicas/guias-e-planos/diagnosticar-
343		para-cuidar-estrategia-nacional-de-vigilancia-epidemiologica-e-laboratorial.pdf
344	13.	Landim ELAS, Guimarães M do CL, Pereira APC de M. Rede de Atenção à
345		Saúde: integração sistêmica sob a perspectiva da macrogestão. Saúde em
346		Debate [Internet]. 2019;43(spe5):161–73. Available from:
347		http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-
348		11042019001000161&tlng=pt
349	14.	Ministério da Saúde B. Painel Coronavírus [Internet]. 2020 [cited 2021 Apr 11].
350	• • •	Available from: https://covid.saude.gov.br
351	15.	Ministério da Saúde B. Vacinômetro [Internet]. Brasília: Ministério da Saúde;
352	10.	2021. Available from:
353		https://infoms.saude.gov.br/extensions/SEIDIGI_DEMAS_Vacina_C19/SEIDIG
354		I DEMAS Vacina C19.html
355	16.	Secretaria de Vigilância em Saúde DF. Relatório de Exames RT-PCR – Covid-
356		19 do LACEN-DF [Internet]. Brasília: Secretaria de Saúde do Distrito Federal;
357		2024. Available from: https://info.saude.df.gov.br/relatoriodeexamesrtpcr/
358	17.	Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data–
359		from vision to reality. Eurosurveillance. 2017;22(13):30494.
360	18.	EpiFLU. Global Initiative on Sharting All Influenza Data [Internet]. GISAID;
361		2008. Available from: https://gisaid.org/wiv04/
362	19.	OPAS OPA da S. NEWS. 2021. p. 1 OMS anuncia nomenclaturas simples e
363		fáceis de pronunciar para variantes de interesse e de preocupação do SARS-
364		CoV-2. Available from: https://www.paho.org/pt/noticias/1-6-2021-oms-
365		anuncia-nomenclaturas-simples-e-faceis-pronunciar-para-variantes-interesse-
366		e
367	20.	Brasil. Normas aplicáveis a pesquisas em Ciências Humanas e Sociais.
368	20.	[Internet]. Brasília: Conselho Nacional de Saúde; 2016. p. 44–6. Available
369		from:
370		https://conselho.saude.gov.br/images/comissoes/conep/documentos/NORMA
371		S-RESOLUCOES/Resoluo n 510 - 2016 -
372		Cincias Humanas e Sociais.pdf
373	21.	OPAS OPA da S. Chega ao Brasil o primeiro lote dos 10 milhões de testes
374		comprados pelo Ministério da Saúde via OPAS [Internet]. 2020. p. 1. Available
375		from: https://www.paho.org/pt/noticias/22-4-2020-chega-ao-brasil-primeiro-
376		lote-dos-10-milhoes-testes-comprados-pelo-ministerio-da
377	22.	Moura EC, Cortez-Escalante J, Cavalcante FV, Barreto IC de HC, Sanchez
378		MN, Santos LMP. Covid-19: temporal evolution and immunization in the three
379		epidemiological waves, Brazil, 2020–2022. Vol. 56, Revista de Saúde Pública.
380		scielo ; 2022.
381	23.	Lima FET, Albuquerque NLS de, Florencio S de SG, Fontenele MGM, Queiroz
	_0.	

- APO, Lima GA, et al. Intervalo de tempo decorrido entre o início dos sintomas 382 e a realização do exame para COVID-19 nas capitais brasileiras, agosto de 383 2020*. Vol. 30, Epidemiologia e Serviços de Saúde. scielo ; 2021. 384 24. Agência Brasil S. News. 2021 [cited 2024 Jan 10]. p. 1 Ministério da Saúde 385 promove testagem rápida com voluntários no DF. Available from: 386 https://agenciabrasil.ebc.com.br/saude/noticia/2021-08/ministerio-da-saude-387 faz-promove-testagem-rapida-com-voluntarios-no-df 388 25. ANVISA AN de VS. Resolução. 2020 [cited 2024 Feb 28]. p. 2 RDC ANVISA 389 Nº 377. Available from: https://www.as.saude.ms.gov.br/wp-390 content/uploads/2020/05/Anexo-3-do-BI-nº14-RDC-ANVISA-Nº-377-Autoriza-391 uso-de-testes-rápidos-nas-farmácias.pdf 392 26. Dias V, Carneiro M, Michelin L, Vidal CF de L, Costa L, Ferreira CE dos S, et 393 394 al. Testes sorológicos para COVID-19: Interpretação e aplicações práticas. J 395 Infect Control. 2020;9(2):90-101. 27. de Araújo ESA, Condursi JR, Garmatter LPL. Análise Econômica da 396 Incorporação do Teste rápido de antígeno para Covid-19 versus RT-PCR 397 398 como estratégia de diagnóstico de pacientes sintomáticos no pronto atendimento de uma operadora de saúde do Brasil. Brazilian J Infect Dis 399 [Internet]. 2022;26:101781. Available from: 400 https://www.sciencedirect.com/science/article/pii/S1413867021002506 401 28. Leite JA, Gresh L, Vicari A, Gabastou JM, Perez E, Aldighieri S, et al. COVID-402 19 laboratory preparedness and response in the Americas Region: Lessons 403 learned. Simuunza MC, editor. PLoS One [Internet]. 2021 Jun 404 29;16(6):e0253334. Available from: 405 https://dx.plos.org/10.1371/journal.pone.0253334 406 407 29. Ministério da Saúde B. Entenda as diferenças entre RT-PCR, antígeno e autoteste [Internet]. 2022. p. 1. Available from: https://www.gov.br/saude/pt-408 br/assuntos/noticias/2022/fevereiro/entenda-as-diferencas-entre-rt-pcr-409 antigeno-e-autoteste 410 Naveca F, da Costa C, Nascimento V, Souza V, Corado A, Nascimento F, et 411 30. al. SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P. 1 in 412 Amazonas, Brazil. Virol org. 2021; 413 414
- 415





Figure 1. Monthly number of RT-PCR analyzes carried out at the Central Public

Health Laboratory and number of Covid-19 cases, compared with the SARS-

1


CoV-2 variant predominant in Brasília, 2020 to 2023.



Source: elaborated by the authors.

1

Figure 2. Monthly quantity of RT-PCR analysis carried out at the Central Public Health Laboratory and number of deaths from Covid-19, compared with the SARS-CoV-2 variant predominant in Brasília, 2020 to 2023.




Source: elaborated by the authors.

1

Figure 3. Number of registered deaths, vaccination schedule and predominant SARS-

CoV-2 variants in Brasília, 2020 to 2023.



Source: el by the authors, 2024.

1

Figure 4. Characterization of the number of Covid-19 samples received and sequenced in public and private national and international laboratories for demand in Brasília from 2020 to 2023.